Publications

265 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period from
to

Enter a start and/or end date here, using the following format: DD-MM-YYYY.

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by: Date / Relevance

Conditional inclusion procedure for medicinal products

This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

Publication | 30-07-2020

Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

Zorginstituut Nederland has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult patients with ...

Report | 03-07-2020

International strategic agenda 2020 National Health Care Institute

When performing its tasks, the National Health Care Institute (Zorginstituut Nederland, or ZIN) participates with various other ...

Publication | 30-05-2020

Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions

Zorginstituut Nederland has completed its assessment whether pentosan polysulfate sodium (Elmiron®) is interchangeable with a ...

Report | 28-04-2020

12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group

Zorginstituut Nederland has completed its assessment whether 12 SQ-HDM SLIT (Itulazax®) is interchangeable with a product that ...

Report | 28-04-2020

Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum

Zorginstituut Nederland has completed its assessment whether olaparib (Lynparza®) as a monotherapy for the maintenance treatment ...

Report | 19-03-2020

Trientine tetrahydrochloride (Cuprior®) the treatment of Wilson’s disease

Zorginstituut Nederland has completed its assessment whether trientine tetrahydrochloride (Cuprior®) is interchangeable with a ...

Report | 19-03-2020

Hydroquinine (Inhibin®) for patients with nocturnal muscle cramps

Zorginstituut Nederland has assessed whether hydroquinine (Inhibin®) should be included in the medication reimbursement system ...

Report | 04-03-2020

Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations

Zorginstituut Nederland has completed its assessment whether voretigene neparvovec (Luxturna®) for the treatment of vision loss ...

Report | 17-02-2020

Emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in patients with severe haemophilia A without inhibitors

Zorginstituut Nederland has completed its assessment whether emicizumab (Hemlibra®) for the prophylactic treatment of bleeding in ...

Report | 17-02-2020